[{"orgOrder":0,"company":"Se-cure Pharmaceuticals","sponsor":"Clalit","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"ISRAEL","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Brizo","moa":"Undisclosed","graph1":"Urology","graph2":"Undisclosed","graph3":"Se-cure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Se-cure Pharmaceuticals \/ Clalit","highestDevelopmentStatusID":"1","companyTruncated":"Se-cure Pharmaceuticals \/ Clalit"}]

Find Clinical Drug Pipeline Developments & Deals by Se-cure Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Brizo is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Hyperplasia.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 07, 2022

                          Lead Product(s) : Brizo

                          Therapeutic Area : Urology

                          Highest Development Status : Undisclosed

                          Sponsor : Clalit

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank